SYDNEY, Dec. 4, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce positive final data from a phase II clinical study of paxalisib as first line therapy in patients with glioblastoma (NCT03522298). The results confirm the previously reported safety and...
The Role of Modern Payroll Modern payroll systems are essential to any organization's financial infrastructure in today's rapidly evolving business...
It pays to understand how the international taxation system works before you start selling abroad. Take a glance at the business news just now an...
Deputy, the world’s leading workforce management platform for shift work, today announced the global launch of Deputy Analytics+, a next-generatio...
UNSW Founders, Australia’s most recommended startup accelerator, has partnered with fund manager Luminary Partners to invest $200,000 each into 18...
The present business environment imposes stronger requirements on Australian organizations to match the fast-paced digital-first economy requireme...
Managing data responsibly and effectively for the AI age can give organisations a strong competitive advantage, but many are failing to harness th...
